Very important pharmacogenetic variants landscape and potential clinical relevance in the Zhuang population from Yunnan province
- PMID: 38553524
- PMCID: PMC10980727
- DOI: 10.1038/s41598-024-58092-w
Very important pharmacogenetic variants landscape and potential clinical relevance in the Zhuang population from Yunnan province
Abstract
The gradual evolution of pharmacogenomics has shed light on the genetic basis for inter-individual drug response variations across diverse populations. This study aimed to identify pharmacogenomic variants that differ in Zhuang population compared with other populations and investigate their potential clinical relevance in gene-drug and genotypic-phenotypic associations. A total of 48 variants from 24 genes were genotyped in 200 Zhuang subjects using the Agena MassARRAY platform. The allele frequencies and genotype distribution data of 26 populations were obtained from the 1000 Genomes Project, followed by a comparison and statistical analysis. After Bonferroni correction, significant differences in genotype frequencies were observed of CYP3A5 (rs776746), ACE (rs4291), KCNH2 (rs1805123), and CYP2D6 (rs1065852) between the Zhuang population and the other 26 populations. It was also found that the Chinese Dai in Xishuangbanna, China, Han Chinese in Beijing, China, and Southern Han Chinese, China showed least deviation from the Zhuang population. The Esan in Nigeria, Gambian in Western Division, The Gambia, and Yoruba in Ibadan, Nigeria exhibited the largest differences. This was also proved by structural analysis, Fst analysis and phylogenetic tree. Furthermore, these differential variants may be associated with the pharmacological efficacy and toxicity of Captopril, Amlodipine, Lisinopril, metoclopramide, and alpha-hydroxymetoprolol in the Zhuang population. Our study has filled the gap of pharmacogenomic information in the Zhuang population and has provided a theoretical framework for the secure administration of drugs in the Zhuang population.
Keywords: Personalized administration; Potential clinical relevance; Single nucleotide variants; Very important pharmacogene variant; Zhuang population.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures






Similar articles
-
Genetic polymorphisms of very important pharmacogene variants in the Chinese Lisu population.Per Med. 2023 May;20(3):239-249. doi: 10.2217/pme-2022-0117. Epub 2023 Jul 10. Per Med. 2023. PMID: 37427690
-
The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations.Cancer Chemother Pharmacol. 2024 May;93(5):481-496. doi: 10.1007/s00280-023-04638-0. Epub 2024 Feb 1. Cancer Chemother Pharmacol. 2024. PMID: 38300251
-
Genetic polymorphisms in very important pharmacogenomic variants in the Zhuang ethnic group of Southwestern China: A cohort study in the Zhuang population.Medicine (Baltimore). 2018 Apr;97(17):e0559. doi: 10.1097/MD.0000000000010559. Medicine (Baltimore). 2018. PMID: 29703042 Free PMC article.
-
Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China.Pharmacogenomics J. 2021 Feb;21(1):60-68. doi: 10.1038/s41397-020-0177-y. Epub 2020 Jul 23. Pharmacogenomics J. 2021. PMID: 32699276
-
Genetic polymorphisms of pharmacogenomic VIP variants in the Dai population from Yunnan province.Mol Genet Genomic Med. 2020 Jul;8(7):e1231. doi: 10.1002/mgg3.1231. Epub 2020 Apr 29. Mol Genet Genomic Med. 2020. PMID: 32347657 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous